Yu, Yan
Li, Haobin
Liu, Jing
Liang, Qing
Xie, Juan
Sun, Guangchun https://orcid.org/0000-0002-5879-1621
Clinical trials referenced in this document:
Documents that mention this clinical trial
Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection
https://doi.org/10.1007/s40256-023-00622-4
Funding for this research was provided by:
the Shanghai Municipal Health and Family Planning Commission (202040387, 20194Y0258)
the Fifth People’s Hospital of Shanghai (2018WYZT04, 2020WYZD01)
Shanghai Minhang District Health Commission (mwyjyx05)
Article History
Accepted: 27 November 2023
First Online: 24 December 2023
Declarations
:
: This study was sponsored by the Shanghai Municipal Health and Family Planning Commission (202040387, 20194Y0258), the Fifth People’s Hospital of Shanghai (2018WYZT04, 2020WYZD01), and the Health and Family Commission of Shanghai Minhang District (mwyjyx05).
: Yan Yu, Haobin Li, Jing Liu, Qing Liang, Juan Xie, and Guangchun Sun declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
: Data will be made available upon reasonable request.
: Not applicable.
: GS And YY contributed to the conception of this study and proposed the amendments. JX enrolled the patients, diagnosed whether they have a pulmonary infection and collected the blood samples. HL, YY and JL collected the data, followed-up the patients, and completed data analysis. YY drafted this manuscript. QL revised the manuscript and edited the English.
: The protocol of this study was approved by the Ethics Committee of Fifth People’s Hospital of Shanghai (Ethics Committee approval number: 2019 Lun Shen No. 107) and was registered on the Chinese Clinical Trial Registry (ChiCTR2000033144). All methods were carried out in accordance with atrial fibrillation guidelines and regulations.
: All patients provided written informed consent before enrollment.
: Not applicable.